TABLE 2.
COVID vaccine and infection characteristics of the study population
| Vaccinated | |
| Yes | 1293 (61.81%) |
| No | 799 (38.19%) |
| Doses | |
| One | 456 (35.27%) |
| Two | 837 (64.73%) |
| Type of vaccine | |
| ChAdOx1 nCov‐19 (Covishield) | 1004 (77.64%) |
| BBV 152 (COVAXIN) | 279 (21.57%) |
| SPUTNIK | 4 (0.31%) |
| PFIZER | 3 (0.23%) |
| SINOPHARM | 1 (0.08%) |
| ASTRAZENECA | 1 (0.08%) |
| SINOVAX | 1 (0.08%) |
| Reason for not taking vaccine, 799/2092; 38.19% | |
| Worried about vaccine side effects | 421 (52.69%) |
| Might worsen rheumatic disease | 195 (24.40%) |
| Do not feel it is needed | 98 (12.26%) |
| Fear due to comorbidities | 86 (10.76%) |
| Interaction with current drugs | 81 (10.13%) |
| Vaccine not available | 29 (3.62%) |
| Affordability | 5 (0.6%) |
| Others | |
| No time | 42 (5.25%) |
| Physically challenged | 2 (0.2%) |
| Advised not to take | 1 (0.1%) |
| Surgery | 1 (0.1%) |
| Walking difficulty | 1 (0.1%) |
| On chemotherapy | 1 (0.1%) |
| COVID epidemic has settled | 1 (0.1%) |
| Due to anemia | 1 (0.1%) |
| Previous arm pain | 1 (0.1%) |
| Vaccine‐related side effects, n = 435/1293 | |
| Body pain/myalgia | 328 (25.37%) |
| Fever | 258 (19.95%) |
| Injection site pain | 240 (18.56%) |
| Joint pain, self‐limiting, lasting for 1 to 3 d | 117 (9.04%) |
| Worsening of existing rheumatic disease | 32 (2.47%) |
| Minor flare | 20 (1.54%) |
| Flare requiring stepping up of drugs | 12 (<1%) |
| Major flare requiring hospitalization | 0 |
| Others | |
| Headache | 3 (0.2%) |
| Fatigue | 2 (0.14%) |
| Vomiting and loose stools | 1 (0.07%) |
| Weight gain | 1 (0.07%) |
| Worsened cutaneous psoriasis | 1 (0.07%) |
| New onset cutaneous vasculitis | 1 (0.07%) |
| Discussed with rheumatologist before taking vaccine, n = 1293 | |
| Yes | 849/1293 (65.66%) |
| No | 444/1293 (34.34%) |
| Rheumatologist asked to stop rheumatic drugs | |
| Yes | 489/849 (57.60%) |
| No | 360/849 (42.40%) |
| When to stop vaccine | |
| Before 1 wk | 2 (0.4%) |
| After 1 wk | 477 (97.54%) |
| Before and after 1 wk | 10 (2%) |
| Infected in unvaccinated | n = 137 |
| 1st wave | 65 (47.44%) |
| 2nd wave | 52 (37.96%) |
| Both waves | 20 (14.6%) |
| Treated at | |
| Home | 73 (53.28%) |
| Hospital | 64 (46.72%) |
| Post‐vaccination breakthrough infection | 72 |
| 1st wave | ‐ |
| 2nd wave | 72 (100%) |
| Treated at | |
| Home | 48 (66.66%) |
| Hospital, ward/intensive care unit | 24 (33.33%) |
| Infection after taking vaccine | 72 |
| Partially vaccinated | 58 (80.55%) |
| Fully vaccinated | 14 (19.44%) |